MIAMI, May 10, 2017 — 
Longeveron, a regenerative medicine company, announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase.
The clinical trial is designed to assess the safety, tolerability and efficacy of intravenous infusion of two different doses of Longeveron mesenchymal stem cells (LMSCs) compared to placebo. The DMC reviewed safety data from a five-patient run-in phase where subjects diagnosed with Alzheimer’s disease were given a single infusion of either LMSCs or placebo. Longeveron now has the green light to continue the trial.
FREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, 
Boston, January 25, 2017 – Cytonome/ST, LLC announces it has signed the first application specific agreement to license its proprietary GigaSortTM Technology for commercial scale cell therapy production. A premier pharmaceutical company has signed on for rights to use the technology for their explicit disease indication. They will manufacture a critical cell therapy to address one of the major diseases afflicting aging populations globally.